Drug companies forge partnerships with top schools

by Alan Scher Zagier

(AP)—Pharmaceutical companies that can no longer rely on lucrative patents to drive profits are increasingly teaming up with academia in search of the next big drug discovery.

., Astra Zeneca PLC and and Co. are among the drug makers signing seven-figure, multiyear agreements with schools such as New York University, Harvard and the University of California at San Francisco. The deals give campus scientists access to once-proprietary experimental owned by the corporate labs.

Big Pharma has long sought to profit from campus research. But rather than focus on specific projects, the two sides are now joining forces in unprecedented ways—often as equal partners.

Most rely on "template" agreements that spell out intellectual property and other legal issues.

3 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Pharmaceutical intellectual property laws need reform

Nov 07, 2011

Canada's pharmaceutical intellectual property laws need major reform to encourage and protect innovation in developing new drugs, states an analysis in CMAJ (Canadian Medical Association Journal).

Big Pharma cashes in on HGH abuse

Dec 21, 2012

An Associated Press investigation shows that a federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's ...

Bayer 'disappointed' after losing India patent fight

Sep 26, 2012

Pharmaceutical giant Bayer AG on Wednesday said it was "disappointed" with an Indian ruling that allows a local firm to produce a cheaper copy of its patented drug Nexavar for liver and lung cancer.

Bayer challenges India cancer drug ruling

May 06, 2012

German pharmaceutical giant Bayer AG has challenged a ground-breaking Indian ruling that allowed a local firm to produce a vastly cheaper copy of its patented drug for kidney and liver cancer.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

Nov 26, 2014

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.